- Previous Close
6.91 - Open
6.91 - Bid 6.84 x 100
- Ask 6.94 x 100
- Day's Range
6.77 - 6.99 - 52 Week Range
5.71 - 14.05 - Volume
123,341 - Avg. Volume
203,255 - Market Cap (intraday)
416.52M - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
344.50 - EPS (TTM)
0.02 - Earnings Date Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.12
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Brazil, North America, Europe, the Middle East, South America, the United States, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.
investors.biocerescrops.com/home/default.aspx--
Full Time Employees
June 30
Fiscal Year Ends
Basic Materials
Sector
Agricultural Inputs
Industry
Recent News: BIOX
View More
Performance Overview: BIOX
Trailing total returns as of 2025-01-17, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIOX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIOX
View MoreValuation Measures
Market Cap
416.52M
Enterprise Value
644.97M
Trailing P/E
300.87
Forward P/E
43.10
PEG Ratio (5yr expected)
3.59
Price/Sales (ttm)
0.99
Price/Book (mrq)
1.34
Enterprise Value/Revenue
1.46
Enterprise Value/EBITDA
12.96
Financial Highlights
Profitability and Income Statement
Profit Margin
0.55%
Return on Assets (ttm)
3.10%
Return on Equity (ttm)
1.11%
Revenue (ttm)
441.23M
Net Income Avi to Common (ttm)
2.44M
Diluted EPS (ttm)
0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
38.2M
Total Debt/Equity (mrq)
77.17%
Levered Free Cash Flow (ttm)
--
Research Analysis: BIOX
View MoreCompany Insights: BIOX
BIOX does not have Company Insights